An interventional study of RETAIN and Unrelated videos in Opioid Use Disorder, Bloodstream Infection and Osteomyelitis, sponsored by Boston Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Boston Medical Center · Not applicable, Interventional, and Treatment
This project is a pilot study of an adapted intervention of an existing Opioid Use Disorder (OUD) treatment retention intervention called Recovery Management Checkups (RMC). This intervention has been adapted to better fit the experiences and unique issues of those that have been hospitalized with serious injection related infections (SIRI) based on the findings from a prior qualitative study from the principal investigator. This project plans to test the adapted intervention within a smaller group of participants to assess feasibility, acceptability, and calculate early findings of intervention efficacy.
Hospitalizations for SIRIs are a unique entry point for patients to start their recovery journey with medications for OUD (MOUD), but many people do not remain on long-term treatment, despite evidence that indicates MOUDs reduce death and re-hospitalization after SIRIs.
The study objectives are to:
Findings from this pilot study will result in further intervention refinement to better fit the target population, and serve as the basis for a larger randomized control trial that will have aims focused on more in-depth analysis of the efficacy of this program
1,472 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's enrollment of 40 is below the median of 63 across 1,166 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.
Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the RETAIN intervention will receive Motivational Interviewing targeted to their clinical concerns and personalized support tailored to each participants' specific needs determined by their answers to intake questions.
Other: RETAIN
Control arm participants will be offered different videos or podcast episodes that are unrelated to the study topics of infections, substance use, overdose, and medication management.
Other: Unrelated videos
There are 6 different modules that a participant in the RETAIN intervention group can be placed in: "Reinforce Antibiotic Completion", "Linkage to Antibiotic Treatment/Alternate Plan", "Reinforce Recovery", "Linkage to MOUD/Alternate Plan", "Reinforce Treatment Attendance", and "Harm Reduction Support". Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC).
These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
Number of days on medications for opioid disorder (MOUD)
The timeline follow back (TLFB) method will be used to assess this outcome based on self-report.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Participant recruitment rates
Participant recruitment rates will be calculated by dividing the number of participants enrolled by the number of eligible patients identified.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Feasibility of the RETAIN Intervention based on completion of study visits
The rates of completion of study visits will be calculated by dividing the number of completed study visits by the total number of study visits.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Acceptability of the RETAIN Intervention
Acceptability will be assessed using the Acceptability of Intervention Measure (AIM) which is a 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean and higher scores are associated with better acceptability.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Number of days of antibiotic completion
Self-report yes or no.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Number of days of Opioid use
The TLFB method will be used to assess this outcome based on self-report.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Number of Hospitalizations
The TLFB method will be used to assess this outcome based on self-report.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Number of uncleaned injections
Self Report based on the The Bacterial Skin Index Risk Score (BIRSI) score, which includes questions about alcohol pad and sterile water use, handwashing, rotating injection sites, injecting subcutaneously or in the muscle ("skin/muscle popping"), and clean needle use, was used as a continuous score to measure risk of skin and soft tissue infections.
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
Number of unmonitored opioid use
Self Report based on Opioid use
Time frame: Baseline while hospitalized, then 2 weeks, 6 weeks, 3 months, and 6 months after discharge
MOUD stigma
Partial adaptation of MMT-SMS stigma scale will be used to assess this outcome based on self-report
Time frame: Baseline while hospitalized, and 6 month after discharge
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in May 2026, 16 months.
Of 464 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 16 months is below that.
Counting every sponsor, half of 495 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.